{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-037084","form_type":"8-K","ticker":"MBRX","cik":"0001659617","company_name":"Moleculin Biotech, Inc.","filed_at":"2025-12-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.066979+00:00","generated_at":"2026-05-16T13:58:53.957039+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Moleculin partners with CIC biomaGUNE for preclinical Annamycin glioblastoma study","bullets":["Agreement supplies Annamycin for investigator-initiated preclinical research at CIC biomaGUNE, Spain.","Studies compare intra-arterial L-Annamycin and Free-Annamycin vs Doxil and free doxorubicin in mouse GBM models.","Principal investigator Jesús Ruiz-Cabello to lead the evaluation of tumor progression.","Annamycin holds FDA Fast Track and Orphan Drug Designation for AML and STS lung metastases.","GBM is the most common malignant brain tumor with median survival of 15 months."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-037084","json":"https://secwatch.observer/filing/0001437749-25-037084.json","markdown":"https://secwatch.observer/filing/0001437749-25-037084.md","text":"https://secwatch.observer/filing/0001437749-25-037084.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1659617/000143774925037084/0001437749-25-037084-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1659617/000143774925037084/mbrx20251205_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T13:58:53.957039+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}